000021472 001__ 21472
000021472 005__ 20210129210800.0
000021472 0247_ $$2pmid$$apmid:21919560
000021472 0247_ $$2DOI$$a10.1080/13554794.2011.568502
000021472 0247_ $$2WOS$$aWOS:000302400900009
000021472 0247_ $$2altmetric$$aaltmetric:21808179
000021472 037__ $$aPreJuSER-21472
000021472 041__ $$aeng
000021472 082__ $$a610
000021472 084__ $$2WoS$$aClinical Neurology
000021472 084__ $$2WoS$$aPsychiatry
000021472 084__ $$2WoS$$aPsychology
000021472 1001_ $$0P:(DE-HGF)0$$aSchilbach, L.$$b0
000021472 245__ $$aPharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits.
000021472 260__ $$aLondon [u.a.]$$bPsychology Press$$c2012
000021472 300__ $$a152 - 159
000021472 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000021472 3367_ $$2DataCite$$aOutput Types/Journal article
000021472 3367_ $$00$$2EndNote$$aJournal Article
000021472 3367_ $$2BibTeX$$aARTICLE
000021472 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000021472 3367_ $$2DRIVER$$aarticle
000021472 440_0 $$026026$$aNeuroCase$$v18$$y2
000021472 500__ $$aRecord converted from VDB: 12.11.2012
000021472 520__ $$aDeep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for Parkinson's disease, but can lead to adverse effects including psychiatric disturbance. Little is known about the risk factors and treatment options for such effects. Here, we describe a patient who reproducibly developed stimulation-induced hypomania when using ventrally located electrodes and responded well to pharmacological intervention while leaving the stimulation parameters unchanged to preserve motor benefits. In spite of clinical remission, [¹⁵O]-positron-emission-tomography (PET) demonstrated activation patterns similar to those reported during mania. This case, therefore, highlights an important treatment option of adverse effects of DBS, but also points toward the need for investigations of its risk factors and their underlying neurobiological mechanisms.
000021472 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems (FUEK409)$$cFUEK409$$x0
000021472 536__ $$0G:(DE-HGF)POF2-89572$$a89572 - (Dys-)function and Plasticity (POF2-89572)$$cPOF2-89572$$fPOF II T$$x1
000021472 588__ $$aDataset connected to Web of Science, Pubmed
000021472 650_2 $$2MeSH$$aAntimanic Agents: therapeutic use
000021472 650_2 $$2MeSH$$aBipolar Disorder: drug therapy
000021472 650_2 $$2MeSH$$aBipolar Disorder: etiology
000021472 650_2 $$2MeSH$$aClozapine: therapeutic use
000021472 650_2 $$2MeSH$$aDeep Brain Stimulation: adverse effects
000021472 650_2 $$2MeSH$$aHumans
000021472 650_2 $$2MeSH$$aMale
000021472 650_2 $$2MeSH$$aMiddle Aged
000021472 650_2 $$2MeSH$$aParkinson Disease: therapy
000021472 650_2 $$2MeSH$$aTreatment Outcome
000021472 650_2 $$2MeSH$$aValproic Acid: therapeutic use
000021472 650_7 $$00$$2NLM Chemicals$$aAntimanic Agents
000021472 650_7 $$05786-21-0$$2NLM Chemicals$$aClozapine
000021472 650_7 $$099-66-1$$2NLM Chemicals$$aValproic Acid
000021472 650_7 $$2WoSType$$aJ
000021472 65320 $$2Author$$aSubthalamic nucleus
000021472 65320 $$2Author$$aDeep brain stimulation
000021472 65320 $$2Author$$aParkinson's disease
000021472 65320 $$2Author$$aStimulation-induced hypomania
000021472 65320 $$2Author$$aPharmacological treatment
000021472 65320 $$2Author$$aPositron-emission-tomography (PET)
000021472 7001_ $$0P:(DE-Juel1)131748$$aWeiss, P.H.$$b1$$uFZJ
000021472 7001_ $$0P:(DE-HGF)0$$aKuhn, J.$$b2
000021472 7001_ $$0P:(DE-HGF)0$$aTimmermann, L.$$b3
000021472 7001_ $$0P:(DE-HGF)0$$aKlosterkötter, J.$$b4
000021472 7001_ $$0P:(DE-HGF)0$$aHuff, W.$$b5
000021472 773__ $$0PERI:(DE-600)1497469-1$$a10.1080/13554794.2011.568502$$gVol. 18, p. 152 - 159$$p152 - 159$$q18<152 - 159$$tNeurocase$$v18$$x1355-4794$$y2012
000021472 8567_ $$uhttp://dx.doi.org/10.1080/13554794.2011.568502
000021472 909CO $$ooai:juser.fz-juelich.de:21472$$pVDB
000021472 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000021472 9131_ $$0G:(DE-HGF)POF2-89572$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$v(Dys-)function and Plasticity$$x1
000021472 9141_ $$y2012
000021472 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000021472 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000021472 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000021472 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000021472 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000021472 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000021472 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000021472 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000021472 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000021472 9201_ $$0I:(DE-Juel1)INM-3-20090406$$gINM$$kINM-3$$lKognitive Neurowissenschaften$$x0
000021472 970__ $$aVDB:(DE-Juel1)137462
000021472 980__ $$aVDB
000021472 980__ $$aConvertedRecord
000021472 980__ $$ajournal
000021472 980__ $$aI:(DE-Juel1)INM-3-20090406
000021472 980__ $$aUNRESTRICTED